CStone Pharmaceuticals (HKSE:02616) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02616 CStone Pharmaceuticals HKSE:02616
57 GF Score
Price HK$5.95
GF Value HK$1.07
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

HKSE:02616
57GF Score
CStone Pharmaceuticals HKSE:02616
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CStone Pharmaceuticals (HKSE:02616) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of HK$5.95 is trading 455.6% above its estimated GF Value™ of HK$1.07. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HKSE:02616:

  • Dividends Received:
  • GF Value™: HK$1.07 vs. price of HK$5.95 (455.6% above fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02616 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CStone Pharmaceuticals Business Description

Other Exchanges CSPHF:USAPH4:Germany
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
57GF Score

Get the complete analysis for HKSE:02616

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$5.95
Price
HK$1.07
GF Value